Ofatumumab

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024
NMOSD, Social media, Hellwig, Nervous system, Alzheimer's disease, MD, Ofatumumab, Stroke, German, Pregnancy, Life, Risk, Annual general meeting, Multiple sclerosis, DSM-IV codes, AAN, Health, Migraine, Parkinson's disease, Hypoesthesia, Fatigue, Ruhr University Bochum, Mother, Paresthesia, Infant, Concussion, Spinal cord, Breast milk, Epilepsy, Sclerosis, Disease, Child, Rituximab, Natalizumab, Optic nerve, Brain, Demyelinating disease, Research, Immune system, American Academy, Birth control

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

Genmab Announces Financial Results for the First Nine Months of 2023

Retrieved on: 
Tuesday, November 7, 2023
Sale, BioNTech, Janssen, DKK, Novartis, Interim, USD, AbbVie, Patient, OS, Clothing, Pharmaceutical industry, Genmab, Health, Ofatumumab, Seagen

Revenue was DKK 11,796 million for the first nine months of 2023 compared to DKK 9,368 million for the first nine months of 2022.

Key Points: 
  • Revenue was DKK 11,796 million for the first nine months of 2023 compared to DKK 9,368 million for the first nine months of 2022.
  • Operating expenses were DKK 8,045 million in the first nine months of 2023 compared to DKK 5,676 million in the first nine months of 2022.
  • Operating profit was DKK 3,651 million in the first nine months of 2023 compared to DKK 3,692 million in the first nine months of 2022.
  • Net financial items resulted in income of DKK 1,060 million for the first nine months of 2023 compared to DKK 2,681 million in the first nine months of 2022.

OncoC4 Strengthens Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

Retrieved on: 
Thursday, September 28, 2023
BioNTech, GSK, Bachelor of Science in Human Biology, GSK plc, DNA, IPO, Partnership, HIV, CSO, Cancer, MedImmune, Abid, Research, Bristol Myers Squibb, Doctor of Philosophy, Sale, Business administration, Acquisition, Genome, Chemical engineering, Ofatumumab, Immune system, Purdue University, CPA, CFO, Growth, Entrepreneurship, BMS, Master of Business Administration, Pharmaceutical industry, Management, Novartis

ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief Financial Officer (CFO), effective immediately.

Key Points: 
  • ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief Financial Officer (CFO), effective immediately.
  • Abid brings over 20 years of expertise in financial strategy and business development for public and private life science companies to OncoC4.
  • “We are delighted to welcome Abid, a seasoned CFO to OncoC4’s executive team.
  • Abid Ansari, Chief Financial Officer of OncoC4, added, “OncoC4 is pioneering the development of next-generation biologics and immunotherapies for the treatment of solid tumors.

Genmab Announces Financial Results for the First Half of 2023

Retrieved on: 
Thursday, August 3, 2023
BioNTech, Interim, DLBCL, Cancer, DKK, Janssen, USD, Sale, B-cell lymphoma, U.S. FDA, Novartis, Patient, AbbVie, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Clothing, Pharmaceutical industry, Genmab, Ofatumumab

Revenue was DKK 7,052 million for the first six months of 2023 compared to DKK 5,281 million for the first six months of 2022.

Key Points: 
  • Revenue was DKK 7,052 million for the first six months of 2023 compared to DKK 5,281 million for the first six months of 2022.
  • Operating expenses were DKK 5,118 million in the first six months of 2023 compared to DKK 3,520 million in the first six months of 2022.
  • Operating profit was DKK 1,934 million in the first six months of 2023 compared to DKK 1,761 million in the first six months of 2022.
  • Net financial items resulted in income of DKK 75 million for the first six months of 2023 compared to DKK 1,340 million in the first six months of 2022.

Genmab Announces Financial Results for the First Quarter of 2023

Retrieved on: 
Wednesday, May 10, 2023
BioNTech, Interim, AbbVie, DLBCL, SC, Risk management, DKK, Janssen, Risk, USD, EDT, B-cell lymphoma, Sale, Novartis, Annual report, CEST, Johnson & Johnson, Daratumumab, Environment, BST, Video game, Pharmaceutical industry, Cryptocurrency, Genmab, Ofatumumab

Genmab has filed a request for review of the award before a single “appeal arbitrator.”

Key Points: 
  • Genmab has filed a request for review of the award before a single “appeal arbitrator.”
    Genmab is maintaining its 2023 financial guidance published on February 22, 2023.
  • Genmab will hold a conference call in English to discuss the results for the first quarter of 2023 today, Wednesday, May 10, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT.
  • Actual results or performance may differ materially from any future results or performance expressed or implied by such statements.
  • Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; and HexElect®.

Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

Retrieved on: 
Thursday, April 20, 2023
Sequela, Sclerosis, Cleveland Clinic, Disability, AAN, Infection, Overalls, COVID-19, Aes, Immunoglobulin M, Urinary tract infection, American Academy, CDW, Multiple sclerosis, Barrow Neurological Institute, MS, RMS, Novartis, Patient, Risk, Common, Immunoglobulin G, Septic, American Academy of Neurology, Pneumonia, LLN, Safety, LGG, Disease, Pharmaceutical industry, MD, Ofatumumab

A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified2.

Key Points: 
  • A separate analysis showed that treatment with Kesimpta for up to five years was well-tolerated, with no new or increased safety risks identified2.
  • These data will be presented at the American Academy of Neurology (AAN) Annual Meeting held in Boston and virtually on April 22-27, 2023.
  • Along with the five-year safety analysis, these data support this treatment as a well-tolerated, efficacious treatment option for people living with relapsing multiple sclerosis."
  • "Novartis remains committed to the multiple sclerosis community in our continued study of Kesimpta and to supporting those living with MS and their families throughout their journey."

Genmab Publishes 2022 Annual Report

Retrieved on: 
Wednesday, February 22, 2023
Medicine, AbbVie, Annual report, PDF, SC, Priority review, Biologics license application, Tisotumab vedotin, European Medicines Agency, CET, BioNTech, B-cell lymphoma, Marketing, Patient, Janssen, Prescription Drug User Fee Act, DKK, EST, Regulation of tobacco by the U.S. Food and Drug Administration, U.S. FDA, Genmab, Novartis, Cervical cancer, Follicular lymphoma, Food, USD, Cryptocurrency, Pharmaceutical industry, Medical device, Ofatumumab

COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2022.

Key Points: 
  • COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2022.
  • Below is a summary of business progress in 2022, financial performance for the year and the financial outlook for 2023.
  • Genmab will hold a conference call in English to discuss the full year results for 2022 today, February 22, 2023 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST.
  • Operating profit was DKK 6,357 million in 2022 compared to DKK 3,018 million in 2021.

Genmab Announces Financial Results for the First Half of 2022

Retrieved on: 
Wednesday, August 10, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Interim, Daratumumab, Johnson & Johnson, United States dollar, AbbVie, Patient, Novartis, U.S. FDA, DKK, BLA, Janssen, Food, USD, Online gambling, Pharmaceutical industry, Ofatumumab, Genmab

Revenue was DKK 5,281 million for the first six months of 2022 compared to DKK 3,553 million for the first six months of 2021.

Key Points: 
  • Revenue was DKK 5,281 million for the first six months of 2022 compared to DKK 3,553 million for the first six months of 2021.
  • Operating expenses were DKK 3,520 million in the first six months of 2022 compared to DKK 2,234 million in the first six months of 2021.
  • Operating profit was DKK 1,761 million in the first six months of 2022 compared to DKK 1,319 million in the first six months of 2021.
  • 40, Genmab is raising its 2022 financial guidance published on May 11, 2022, driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the foreign exchange impact of the strong US Dollar.

Genmab Announces Financial Results for the First Quarter of 2022

Retrieved on: 
Wednesday, May 11, 2022
Interim, Food, SC, Johnson & Johnson, DKK, AbbVie, Patient, Cytokine release syndrome, Review, Clinical trial, Regulation of tobacco by the U.S. Food and Drug Administration, Daratumumab, Novartis, B-cell lymphoma, Follicular lymphoma, U.S. FDA, USD, Pharmaceutical industry, Music, Ofatumumab, Janssen, Halozyme

Revenue was DKK 2,119 million for the first three months of 2022 compared to DKK 1,581 million for the first three months of 2021.

Key Points: 
  • Revenue was DKK 2,119 million for the first three months of 2022 compared to DKK 1,581 million for the first three months of 2021.
  • Operating expenses were DKK 1,605 million in the first three months of 2022 compared to DKK 1,049 million in the first three months of 2021.
  • April: Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the first cohort of the EPCORE NHL-1 phase 1/2 clinical trial evaluating epcoritamab.
  • Genmab is updating the lower end of its 2022 financial guidance published on February 16, 2022, driven by increased royalty revenue related to net sales of DARZALEX.

Novartis' Kesimpta is Poised for Strong Growth in the European Multiple Sclerosis Market, Spherix Global Insights Reports

Retrieved on: 
Tuesday, April 5, 2022
HCP, DMTS, Nephrology, Mark (given name), DMT, Multiple sclerosis, Neurology, Heat, Growth, Patient, FDO, Research, Biogen, Interferon, Environment, Diroximel fumarate, Novartis, Roche, Neutralizing antibody, MS, RMS, BTK, Parallel, Merck KGaA v. Integra Lifesciences I, Ltd., RRMS, Sanofi, S1P, Disease, Fine chemical, Pharmaceutical industry, Ozanimod, Dimethyl fumarate, Ofatumumab, EU, Fingolimod

EXTON, Pa. , April 5, 2022 /PRNewswire/ -- Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the multiple sclerosis (MS) market in Europe through their RealTime Dynamix™: Multiple Sclerosis (EU) service since 2017.

Key Points: 
  • EXTON, Pa., April 5, 2022 /PRNewswire/ -- Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the multiple sclerosis (MS) market in Europe through their RealTime Dynamix: Multiple Sclerosis (EU) service since 2017.
  • Insights uncovered include the continued shift towards oral and monoclonal antibody (mAb) disease modifying therapies (DMTs) and the changing dynamics within drug classes.
  • Kesimpta has seen strong uptake thus far, with the majority of respondents reporting access to and prescribing of the brand.
  • Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.